Castle Biosciences COO sells 4,152 shares at $33-34
Castle Biosciences’ COO exercised options and executed pre-planned stock sales while retaining a significant indirect position through a family trust.
Rhea-AI Filing Summary
CASTLE BIOSCIENCES INC (CSTL) reported that Chief Operating Officer Kristen M. Oelschlager exercised stock options for 4,152 shares of common stock at an exercise price of $3.38 per share on September 1, 2026, then sold 3,952 shares at a weighted-average price of $33.36 and an additional 200 shares at $34.02 in sale transactions made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. She also reports indirect ownership of 72,649 shares held by the Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,152 shares ($125K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Oelschlager Kristen M
Role
Chief Operating Officer
Sold
4,152 shs ($139K)
Approx. gross sale proceeds
$139K
Approx. exercise cost
$14K
Approx. pre-tax spread
$125K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F1, F5 | 4,152 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 4,152 | $3.38 | $14K |
| Sale | Common Stock F1, F3 | 3,952 | $33.36 | $132K |
| Sale | Common Stock F1 | 200 | $34.02 | $7K |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 12,458 contracts (Direct);
Common Stock — 13,356 shares (Direct);
Common Stock — 72,649 shares (Indirect, The Fritz Shorter Trust)
Footnotes (5)
- F1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026.
- F2. Includes 68 shares acquired on August 31, 2026, under the Issuer's employee stock purchase plan.
- F3. This transaction was executed in multiple trades at prices ranging from $33.015 to $33.900, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. Held by the Fritz Shorter Trust of which the Reporting Person and her spouse are the trustees and beneficiaries.
- F5. The shares subject to the option are fully vested.
Key Figures
Options exercised: 4,152 shares
Exercise price: $3.38 per share
Shares sold (primary block): 3,952 shares
+5 more
8 metrics
Options exercised
4,152 shares
Stock options for common stock exercised on September 1, 2026
Exercise price
$3.38 per share
Exercise price of options for 4,152 shares of common stock
Shares sold (primary block)
3,952 shares
Common stock sale on September 1, 2026 at a weighted-average price
Weighted-average sale price
$33.36 per share
Price for 3,952 shares sold in multiple trades on September 1, 2026
Additional shares sold
200 shares
Separate sale of common stock on September 1, 2026
Price for additional shares
$34.02 per share
Reported price for the 200-share sale transaction
Indirect trust holdings
72,649 shares
Common stock held by the Fritz Shorter Trust
Employee stock purchase plan shares
68 shares
Shares acquired on August 31, 2026 under the employee stock purchase plan
Key Terms
Rule 10b5-1 plan, weighted-average sale price, employee stock purchase plan, beneficiaries
4 terms
Rule 10b5-1 plan regulatory
"These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted-average sale price financial
"The price reported above reflects the weighted-average sale price."
employee stock purchase plan financial
"Includes 68 shares acquired on August 31, 2026, under the Issuer's employee stock purchase plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
beneficiaries financial
"Held by the Fritz Shorter Trust of which the Reporting Person and her spouse are the trustees and beneficiaries."
Beneficiaries are the people or organizations designated to receive benefits, such as money or assets, from a financial arrangement like a trust, insurance policy, or retirement plan. They matter to investors because choosing the right beneficiaries ensures that assets are passed on according to their wishes, providing financial security or support to loved ones when needed. Think of beneficiaries as the intended recipients of a gift or inheritance.
FAQ
What did CSTL’s Chief Operating Officer report in the latest Form 4?
The Chief Operating Officer, Kristen M. Oelschlager, exercised options for 4,152 shares of Castle Biosciences common stock at $3.38 per share and on the same day reported sales of most of those shares in two transactions under a Rule 10b5-1 plan.
What options did the COO of CSTL exercise in this Form 4?
She exercised stock options covering 4,152 shares of Castle Biosciences common stock at an exercise price of $3.38 per share. The option was fully vested and is scheduled to expire on March 12, 2029 according to the disclosure.
Was the CSTL Form 4 activity under a Rule 10b5-1 trading plan?
Yes. The filing states that these transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 17, 2026, indicating the trades were pre-arranged rather than initiated on a discretionary basis at the time of sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.
